These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26177892)

  • 1. A Review of Nebivolol Pharmacology and Clinical Evidence.
    Fongemie J; Felix-Getzik E
    Drugs; 2015 Aug; 75(12):1349-71. PubMed ID: 26177892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
    Paton DM
    Drugs Today (Barc); 2017 Jan; 53(1):19-26. PubMed ID: 28387384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Byvalson--a beta blocker/ARB combination for hypertension.
    Med Lett Drugs Ther; 2016 Sep; 58(1503):115-7. PubMed ID: 27603961
    [No Abstract]   [Full Text] [Related]  

  • 6. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
    Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.
    Cicero AFG; Kuwabara M; Borghi C
    Drugs; 2018 Nov; 78(17):1783-1790. PubMed ID: 30426333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure.
    Del Sindaco D; Tinti MD; Monzo L; Pulignano G
    Clin Interv Aging; 2010 Dec; 5():381-93. PubMed ID: 21152240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension.
    Mende CW; Giles TD; Bharucha DB; Ferguson WG; Mallick M; Patel MD
    J Clin Hypertens (Greenwich); 2017 Jun; 19(6):632-639. PubMed ID: 28075064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.
    Ishak J; Rael M; Punzi H; Gradman A; Anderson LM; Patel M; Ali S; Ferguson W; Neutel J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):143-149. PubMed ID: 29105958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol: a new antihypertensive agent.
    Gray CL; Ndefo UA
    Am J Health Syst Pharm; 2008 Jun; 65(12):1125-33. PubMed ID: 18541682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients.
    Borghi C; Acelajado MC; Gupta Y; Jain S
    J Hum Hypertens; 2017 Oct; 31(10):605-610. PubMed ID: 28382958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans.
    Velasco A; Solow E; Price A; Wang Z; Arbique D; Arbique G; Adams-Huet B; Schwedhelm E; Lindner JR; Vongpatanasin W
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H118-24. PubMed ID: 27199121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease.
    Howlett JG
    Can J Cardiol; 2014 May; 30(5 Suppl):S29-37. PubMed ID: 24750980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Seleme VB; Marques GL; Mendes AEM; Rotta I; Pereira M; Júnior EL; da Cunha CLP
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):165-180. PubMed ID: 32710438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.
    Coats A; Jain S
    J Hum Hypertens; 2017 Jun; 31(6):376-381. PubMed ID: 28252041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
    Frishman WH; Henderson LS; Lukas MA
    Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.